Clinical Trials - April 24, 2026
Takeda reports additional Phase 3 clinical insights on TAK-279
Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).
Sweden - April 21, 2026
Stable Swedish health exports despite an uncertain surrounding world
This is according to Swecare's Health Export Barometer 2026 launched today, April 21.
CDMO - April 21, 2026
Nanologica receives SEK 2 million order from customer in India
Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga.
Subscribe - April 20, 2026
Subscriber benefit: 20% discount on your Vitalis ticket
If you are a NLS Subscriber or NLS Member you get 20% off on a conference ticket to Vitalis 2026.
In a new job - April 20, 2026
Günther Mårder leaves the Board of RaySearch after being arrested
Mårder was arrested April 17 on probable cause on suspicion of serious insider trading.
Business article - April 20, 2026
White paper: Systemic barriers preventing women from reaching leadership roles
The Nordic life science sector is losing highly qualified female talent in top leadership positions, according to a new white paper published by Women in Life Science Denmark (WiLD), WiLD Norway, and VILDA Sweden.
